Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
Clinical trial NCT06291987 · RECRUITING
Trial details
- NCT number
- NCT06291987
- Sponsor
- University of Chicago
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-19
- Primary completion
- 2026-05-01
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.